Last updated on August 2018

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Brief description of study

The purpose of the trial is to determine the long-term safety and efficacy of RPC1063 in patients diagnosed with moderate to severe ulcerative colitis.

Detailed Study Description

The trial is an open label extension study. Eligible patients from the RPC01-3101 and RPC01-202 trials will have the option to enroll in this trial to receive study medication for up to 5 years or until marketed approval

Clinical Study Identifier: NCT02531126

Contact Investigators or Research Sites near you

Start Over

Celgene True North Study True ...

Vitebsk Regional Clinical Hospital
Vitebsk, Belarus
  Connect »